Art. -Nr.: HY-B0281A

Ranitidine hydrochloride

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA₂ values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.86%
CAS. Nr.: 66357-59-3
Formel: C₁₃H₂₃ClN₄O₃S
Molecular Weight:350.86

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ranitidine hydrochloride Chemical Structure

CAS. Nr.: 66357-59-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

H₂ Receptor

Alle Histamine Receptor Isoform-spezifische Produkte anzeigen :

In Vivo

Ranitidine (0.03-3 mg/kg; i.v.; once) hydrochloride inhibits Histamine (HY-B1204)- and Pentagastrin (HY-A0261)-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat^[1].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) hydrochloride reduces the number of CD11b⁺Ly6C^hi cells in the spleen and bone marrow of BALB/c mice^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) hydrochloride inhibits lung metastasis in BALB/c mice bearing 4T1 breast cancer^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; for 14 days) hydrochloride inhibits primary tumor growth in the E0771 breast cancer model of C57BL/6 mice^[2].
Ranitidine (dose enabling mice to ingest 6-8 mg/kg per day; added to drinking water; changed every 3 days; treatment starting from weaning (~4 weeks) until the end of the experiment (23-26 weeks)) hydrochloride increases the latency of breast tumorigenesis and reduces the number of tumors in LKB1^-/-NIC mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Wistar rats (100 to 120 g) were anaesthetized with sodium pentobarbitone (50 mg/kg i.p.), and intravenous with Histamine (100 μg/kg/min) or Pentagastrin (1 μg/kg/min)^[1].
Dosage:

0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1 mg/kg, 3 mg/kg
Administration:

i.v.; once
Result:

Inhibited Histamine- and Pentagastrin-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat.

Animal Model:

BALB/c female mice (5-6-8 week old), orthotopic breast cancer model by injecting 100,000 4T1 cells subcutaneously into the mammary fat pad near the fourth nipple^[2].
Dosage:

8 mg/kg
Administration:

Oral administration, every other day, 8 days
Result:

Decreased the proportion of CD11b⁺Ly6C^hi monocytic cells in the spleen and inhibited lung metastasis.

Animal Model:

C57BL/6 female mice (6-8 week old), orthotopic breast cancer model by injecting 200,000 E0771 cells in 100 μL of Matrigel subcutaneously into the mammary fat pad near the fourth nipple^[2].
Dosage:

8 mg/kg
Administration:

Oral administration, every other day, 8 days
Result:

Decreased primary tumor growth starting from approximately day 13 post-tumor cell injection.

Animal Model:

LKB1^-/-/NIC female mice (weaned at about 4 weeks old), spontaneous tumor development model starting from weaning^[2].
Dosage:

6-8 mg/kg
Administration:

Oral administration, every 3 days, from weaning until the end of the experiment
Result:

Increased the latency of tumorigenesis by an additional 24 days and reduced the average number of tumors per mouse.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 66357-59-3
Appearance Solid
Molecular Weight 350.86
Formel C₁₃H₂₃ClN₄O₃S
Color Off-white to yellow
SMILES

CN/C(NCCSCC1=CC=C(CN(C)C)O1)=C\[N+]([O-])=O.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (4)

All

Sort by:

Journal Impact Factor

Cell Host Microbe

Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]

2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313
Brain Sci

Paraventricular Mast Cell-Derived Histamine Activates CRH Neurons to Mediate Adult Visceral Hypersensitivity Induced by Neonatal Maternal Separation. [Abstract]

2023 Nov 16;13(11):1595. PMID: 38002554
Indian J Ophthalmol

Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]

2026 Feb 1;74(2):250-258. PMID: 41581041
Kingston University

2026.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 50 mg/mL (142.51 mM)

DMSO : 50 mg/mL (142.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8501 mL

14.2507 mL

28.5014 mL

5 mM

0.5700 mL

2.8501 mL

5.7003 mL

10 mM

0.2850 mL

1.4251 mL

2.8501 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 110 mg/mL (313.52 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Daly MJ, et al. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol. 1981 Jan;72(1):49-54. [Content Brief]

[2]. Vila-Leahey A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016 Mar 10;5(7):e1151591. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.8501 mL	14.2507 mL	28.5014 mL	71.2535 mL
	5 mM	0.5700 mL	2.8501 mL	5.7003 mL	14.2507 mL
	10 mM	0.2850 mL	1.4251 mL	2.8501 mL	7.1253 mL
	15 mM	0.1900 mL	0.9500 mL	1.9001 mL	4.7502 mL
	20 mM	0.1425 mL	0.7125 mL	1.4251 mL	3.5627 mL
	25 mM	0.1140 mL	0.5700 mL	1.1401 mL	2.8501 mL
	30 mM	0.0950 mL	0.4750 mL	0.9500 mL	2.3751 mL
	40 mM	0.0713 mL	0.3563 mL	0.7125 mL	1.7813 mL
	50 mM	0.0570 mL	0.2850 mL	0.5700 mL	1.4251 mL
	60 mM	0.0475 mL	0.2375 mL	0.4750 mL	1.1876 mL
	80 mM	0.0356 mL	0.1781 mL	0.3563 mL	0.8907 mL
	100 mM	0.0285 mL	0.1425 mL	0.2850 mL	0.7125 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ranitidine hydrochloride

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ranitidine hydrochloride

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ranitidine hydrochloride

Alle Histamine Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ranitidine hydrochloride Related Classifications

HY-B0281A Related Classifications